A randomized, double-blind, placebo-controlled study of the effects of pomegranate extract on rising PSA levels in men following primary therapy for prostate cancer - Pantuck, A J; Pettaway, C A; Dreicer, R; Corman, J; Katz, A; Ho, A; Aronson, W; Clark, W; Simmons, G; Heber, D (Prostate cancer and prostatic diseases, 2015)
Keywords: 631/92/349; 692/699/67/1059; 692/699/67/1857; 692/699/67/589/466; Aged; Antineoplastic Agents, Phytogenic - administration & dosage; Antineoplastic Agents, Phytogenic - adverse effects; Antineoplastic Agents, Phytogenic - therapeutic use; Biomedical and Life Sciences; Biomedicine; Cancer Research; Combined Modality Therapy; Control methods; Disease Progression; Double-blind studies; Genotypes; Humans; Hypothesis testing; Immune system; Juices; Lythraceae - chemistry; Male; Manganese; Medication Adherence; Middle Aged; Neoplasm Grading; Neoplasm Staging; original-article; Plant Extracts - administration & dosage; Plant Extracts - adverse effects; Plant Extracts - therapeutic use; Polymorphism, Single Nucleotide; Pomegranate; Prolongation; Prostate cancer; Prostate-Specific Antigen - blood; Prostatic Neoplasms - blood; Prostatic Neoplasms - drug therapy; Prostatic Neoplasms - genetics; Prostatic Neoplasms - pathology; Statistical analysis; Superoxide dismutase; Superoxide Dismutase - genetics; Testing; Therapy; Treatment Outcome; United States